Tata Elxsi Limited has informed the Exchange about Transcript
TATAELXSI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tata Elxsi posted Q4 FY26 revenue of ₹993.8 crores, up 0.9% quarter-on-quarter in constant currency terms. Transportation grew 0.2% QoQ with OEM clients now contributing 77% of vertical revenue, Healthcare and Life Sciences de-grew 13.1% QoQ due to expected deal closures slipping to Q1 FY27, and Media and Communications rose 5.6% QoQ. EBITDA margin improved 130 basis points sequentially to 24.6%, with the CFO attributing ~150-155 bps to currency tailwinds, 65 bps to operating leverage, partly offset by 90 bps salary hike impact. Notable wins included an ODC for Japan's Terumo Corporation, a strategic deal with a new-age APAC OEM, and a multi-year deal with a world-leading device OEM. Management revised FY27 growth aspiration from double-digit to higher single-digit citing healthcare slippage and geopolitical uncertainty, while guiding to exit Q4 FY27 at around 27% PBT margin.
Margin trajectory remains a key positive with clear path toward 27% PBT exit rate, supported by operational efficiencies and AI-led productivity. However, the downward revision in FY27 growth aspiration and the 13% healthcare decline signal near-term revenue headwinds, likely keeping the stock range-bound with limited catalysts until healthcare deal closures materialise in Q1 FY27.